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During the last 10 to 15 years, many reports
have published patency rates for polytetrafluoroeth-
ylene (PTFE), Dacron, and human umbilical vein
for suprageniculate bypass graft procedures that are
comparable to the rate for autologous saphenous
vein.3,4 Sparing the autologous saphenous vein has
the advantage that it can be used later in more distal
procedures and coronary bypass graft procedures.5
Supported by early satisfactory results with the use
of thin-walled, stretched PTFE as a suprageniculate
bypass graft material,4,6-8 a prospective randomized
trial was designed to evaluate the effectiveness of
reversed saphenous vein grafting in comparison with
that of PTFE bypass grafting in above-knee arterial
reconstructions. The aim of the study was to answer
the following questions:
1. Is there a difference in cumulative patency rates
between saphenous vein and PTFE bypass grafts?
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Femoropopliteal bypass grafting has been shown
to be an effective form of treatment for arterial occlu-
sive disease in patients with severe claudication or crit-
ical ischemia. For infrageniculate femoropopliteal
bypass procedures, it has been demonstrated that
autologous saphenous veins provide the best possible
conduit for bypass grafting.1,2
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Objective: Despite many clinical studies, there is still uncertainty as to whether venous
material is superior to polytetrafluoroethylene for femoropopliteal reconstruction prox-
imal to the knee joint. Supported by early satisfactory results with thin-walled, stretched
polytetrafluoroethylene for suprageniculate bypass grafts, a prospectively randomized
clinical trial was designed to evaluate the effectiveness of reversed saphenous vein in
comparison with that of polytetrafluoroethylene in above-knee arterial reconstruction.
Methods: In a 3-year period, 151 above-knee femoropopliteal bypass graft operations
were performed in 136 patients (77 male, 59 female). The indication for operation was
severe claudication in 120 cases, rest pain in 20 cases, and ulceration in 11 cases. For the
bypass graft, a reversed saphenous vein was used in each of 75 cases, and a polytetraflu-
oroethylene prosthesis was used in each of 76 cases. Preoperative risk factors were dia-
betes (24%), a history of myocardial infarction (23%), and current status with respect to
smoking (74%). There was no hospital mortality; 5% of patients had minor postopera-
tive complications.
Results: After 2 years, the primary patency was 83% for saphenous vein and 67% for poly-
tetrafluoroethylene (P = .065); the secondary patency was 83% for saphenous vein and
77% for polytetrafluoroethylene (P = .298). During a follow-up period of 2 years, we
found no statistically significant difference in primary and secondary patency between
saphenous vein and polytetrafluoroethylene. We found no predictive factor for occlusion
of either bypass graft. 
Conclusion: The use of polytetrafluoroethylene above the knee is a reasonable alternative
in femoropopliteal bypass grafting that is associated with acceptable short-term patency
rates. (J Vasc Surg 2000;32:278-83.)
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2. What are the consequences of bypass graft failure?
3. If PTFE is used, will the autologous vein be avail-
able and usable for more distal procedures later?
The follow-up period of the investigation will be
5 years. This article deals with the 2-year results of
the study. We realize that differences between the
two graft types that are not apparent during short-
term follow-up might well be expected after a longer
period of follow-up.1,4,6,7,9
PATIENTS AND METHODS
The study was carried out between January 1993
and December 1996. All patients with severe claudi-
cation, rest pain, or tissue loss undergoing
femoropopliteal reconstruction with the site of the
distal anastomosis above the knee joint were eligible
for the study. Above-knee grafting was performed
when the above-knee popliteal artery was patent and
suitable for anastomosis at operation. A patient was
excluded if an arterial bypass graft procedure had
previously been performed in the same leg or if the
greater saphenous vein had been removed earlier. 
A history was obtained for each patient; it includ-
ed information on risk factors related to arterial
occlusive disease (diabetes, cardiac history, and smok-
ing habits). In every patient, an arteriography and a
hemodynamic profile were obtained. Arteriography
was performed by the translumbar route or trans-
femorally through use of the Seldinger technique.
The popliteal and distal arteries were scored as open
or occluded.10 The hemodynamic profile comprised
the ankle blood pressures and the velocity profile of
the common femoral, popliteal, and distal arteries at
the level of the ankle.
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During the operation, the operating surgeon
determined the quality of the greater saphenous vein.
If the vein was suitable for bypass grafting (ie, it had
a diameter of more than 4 mm proximally and 3 mm
distally) then randomization took place. Patients
were not included in the study when the vein was
unsuitable for use as a bypass graft. Either the
reversed vein or a stretched, thin-walled 6-mm PTFE
prosthesis (WL Gore, Flagstaff, Ariz) was used.
Preoperatively, an intravenous dose of Cefamandole
1 g was administered. The operation was performed
after administration of general or regional anesthesia.
Anastomoses were end to side, and continuous 6-0
Prolene sutures, proximal to the common femoral
artery and distal to the popliteal artery, were used.
Before arterial occlusion, a bolus of 5000 IE of
heparin was administered. Postoperative anticoagula-
tion therapy consisted of coumarin during the first 6
months (with an international normalized ratio
between 2 and 4); this was followed by acetylsalicylic
acid (38 mg daily). 
Patients were examined at 6 weeks, 3 months, 6
months, and 1 year and every year thereafter.
Fig 1. Primary patency over time.
Table I. Preoperative arteriography
No. of 
patent tibial Vein Occluded vein PTFE Occluded PTFE
arteries N (%) N (%) N (%) N (%)
3 43 (57) 4 (5) 37 (49) 11 (14)
2 21 (28) 5 (7) 26 (34) 7 (9)
1 11 (15) 1 (1) 13 (17) 2 (3)
Totals 75 11 (15) 76 20 (26)
Examination consisted of a hemodynamic profile, a
physical examination, and the taking of a history.
Graft occlusion was determined to have developed if
there was a drop in distal blood pressure of more
than 20% and a velocity profile consistent with col-
lateral flow in the distal popliteal artery. If a PTFE
bypass graft occluded and the occlusion was detect-
ed within 7 days, a thrombectomy was performed.
In all other cases, a new operation was not consid-
ered necessary if the patient had mild claudication.
In cases of rest pain or necrosis, redo bypass graft
procedures were performed.
The primary end point of the study was an open
or occluded bypass graft at the end of the second
year. Patients could be included in the study twice
for primary operation on the left or the right limb.
Analysis of the primary end point was performed for
each limb. A Cox proportional hazard analysis was
used to determine the influence of preoperative risk
factors on patency of the bypass graft.
The study protocol was approved by the
Institutional Review Board of the Red Cross Hospital,
The Hague. Patient consent was obtained in all cases. 
RESULTS
Between January 1993 and December 1996,
151 bypass graft operations were performed in 136
patients. The group consisted of 77 males (57%) and
59 females (43%). The indication for surgery was
severe claudication in 120, rest pain in 20, and
necrosis in 11 cases. 
Preoperative risk factors for vascular occlusive
disease were diabetes (N = 33; 24%), previous
myocardial infarction (N = 31; 23%), and cigarette
smoking (N = 101; 74%). The risk factors were
equally divided between those who received venous
bypass grafts and those who received PTFE bypass
grafts.
Through the use of preoperative arteriograms,
the outflow arteries of all legs operated on were clas-
sified according to the number of patent distal arter-
ies10 (Table I). Reversed vein was used 75 times, and
6-mm stretched PTFE prostheses were used 76
times. Of the patients with bilateral reconstructions,
five underwent bilateral construction with PTFE
grafts only, two with venous grafts only, and eight
with both venous and PTFE grafts. The operating
time was significantly longer for venous bypass grafts
(mean, 105 minutes) than for PTFE grafts (mean,
73 minutes; P = .002). Superficial wound infection
was seen in seven cases (PTFE grafts, 3; venous
grafts, 4). None of these infections necessitated
reoperation or resulted in loss of the bypass graft.
None of the patients died in the hospital. After 1
year of follow-up, 13 patients had died, 12 with
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Fig 2. Secondary patency over time.
Table II. Relative risk for occlusion
Relative risk Confidence limits
Sex 0.66 0.33-1.32
Age 1.00 0.97-1.04
Diabetes 1.82 0.91-3.63
Myocardial infarction 0.62 0.26-1.48
Smoking 1.28 0.64-2.55
Cox proportional hazard analysis.
patent bypass grafts and 1 with an occluded bypass
graft. After 2 years, 16 patients had died, 14 with
open and 3 with occluded bypass grafts. Of the
remaining 133 cases, eight were lost to follow-up.
After 2 years, the overall primary patency rate
was 75% (n = 100). Saphenous vein had a patency
rate of 83 % (n = 49) and PTFE a patency rate of
67% (n = 51; P = .065; Table III; Fig 1). After rein-
tervention, the secondary patency rate was 80%
(vein, 83%; PTFE, 77%; P = .298; Table IV; Fig 2).
In 10 cases there was an occluded saphenous
bypass graft. Thrombolytic therapy was not per-
formed in our hospital during the time of the study.
Reintervention was performed whenever the patient
experienced severe disabling claudication or rest
pain; in four instances it was necessary to perform a
below-knee bypass graft, three times with PTFE and
one time with a human umbilical vein graft (Dardik
Biograft; Bio-Vascular, Inc, St Paul, Minn). In one
case, we performed an above-knee PTFE bypass
graft. In one case, after multiple revisions the leg was
lost nearly 2 years after the initial operation because
of ischemia.
In 21 cases, there was an occluded PTFE bypass
graft. Thrombectomy was performed six times; it
was successful in all cases. These bypass grafts were
considered “secondary patent.” Below-knee bypass
grafting was performed with PTFE in seven cases,
and we could use the ipsilateral saphenous vein in
three cases.
The Cox proportional hazard analysis showed no
significant predictive value for the presence of dia-
betes mellitus, myocardial infarction, or smoking
with regard to occlusion of either venous or PTFE
bypass grafts (Table II). In addition, the number of
open tibial arteries did not have a predictive value
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with regard to occlusion of the bypass graft (Table
I); this was true for both venous and PTFE bypass
grafts.
DISCUSSION
The question of the best material for above-knee
bypass graft surgery (PTFE vs vein) continues to be
controversial. For some authors, PTFE is the prima-
ry choice for bypass graft material3,4,7,9; for others, it
is not.11-13 However, most of the studies have been
designed with either no controls or historical con-
trols or have been nonrandomized investigations in
which vein and PTFE were compared; an exception
is the multicenter trial by Veith et al.1 The current
study differs from that of Veith et al in that 79% of
patients in our series had claudication with a walking
distance of less than 50 m, whereas all of the patients
in the Veith study had critical ischemia.
In the current prospectively randomized study,
we found no statistically significant difference in
cumulative patency rates between the venous and
PTFE bypass grafts up to 2 years after above-knee
bypass graft surgery, the primary patency rates being
83% and 67%, respectively, and the secondary paten-
cy rates being 83% and 77%, respectively (P = .298).
This could support the assumption that PTFE can
be used with acceptable patency for treatment of
occlusive disease of the superficial femoral artery,
although there is a clear trend for venous bypass
graft to perform better in the long run. However, it
should be acknowledged that a possible limitation to
this study is the relatively short follow-up. A statisti-
cally significant difference in patency between vein
and PTFE might become evident after a longer time.
The population of patients that we operated on
consisted largely of individuals with severe claudica-
Table III. Primary patency life table
Time (wk) Open (n) Occluded (n) LFU (n) Died (n) Patency (%) SEM
Vein
0 75 — — — 100 —
6 69 3 1 2 95 3.0
12 64 3 — 2 92 3.2
26 58 3 1 2 87 4.0
52 56 1 1 — 84 4.4
104 49 — 3 3 81 4.8
PTFE
0 76 — — — 100 —
6 75 1 — — 99 1.3
12 66 6 — 3 91 3.3
26 58 3 1 4 84 4.2
52 52 6 — — 77 4.9
104 45 5 1 1 67 5.6
LFU, Lost for follow-up.
tion (79%). A consideration in the decision for oper-
ative intervention was the risk of complications. The
number of major and minor complications was small
in our series and did not differ between the two
types of bypass graft. For our 151 operations, there
was no hospital mortality, and there were no in-hos-
pital occlusions of bypass grafts. We therefore con-
sider the above-knee bypass graft a safe procedure,
even in patients with disabling claudication.
What were the consequences of bypass graft fail-
ure in our study? In the group of 76 PTFE bypass
grafts, 21 occluded. Six of these patients underwent
successful thrombectomy, and in eight a new opera-
tion was not considered necessary. In each of seven
cases, a below-knee bypass procedure was per-
formed, four times with PTFE and three times with
ipsilateral vein. Thus, in 31 occluded bypass grafts in
151 cases, the veins that were “saved” were used
three times. None of the patients needed the vein for
coronary bypass graft procedures within the follow-
up period. Accordingly, is it realistic to save the
saphenous vein for later, more distal procedures? We
can see, even in this small group of patients, that the
use of saphenous vein does result in fewer occlusions
and fewer reoperations. Moreover, the need for
coronary vein bypass graft procedures decreases
because of the use of mammary arteries and percu-
taneous techniques.
To be sure, there are advantages to the use of
PTFE. First, the operating time is significantly small-
er, which could be beneficial when compromised
patients are being treated. Second, we found that
none of the risk factors that are described in other
studies had a negative influence on the patency of
the PTFE bypass grafts. Third, when thrombosis of
the bypass graft is discovered early after occlusion, a
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thrombectomy is a safe and simple procedure.
However, in this study we found a high though not
statistically significant failure rate in the group of
PTFE bypass grafts that had excellent three-vessel
runoff. This finding could not be explained.
As for the risk factors previously mentioned, we
know from earlier studies that diabetes is such a fac-
tor. Evans et al6 and Prendiville et al14 found that
diabetes has a negative influence on the patency of
bypass grafts; others have found no such effect.4,9 In
the current study, there was no difference in paten-
cy due to the influence of diabetes in either the
PTFE group or the vein group. We also found that
smoking did not negatively influence the patency of
the bypass graft, although not everyone underwrites
this finding,3,9,12,14 Some authors14 found that
runoff did influence the patency of bypass graft
surgery. In the current study, there was no signifi-
cant difference between good and poor runoff for
either venous or PTFE bypass grafts.3,4,6 A reason
for this finding could be the relatively proximal site
of the distal anastomosis.
The current study would seem to justify answer-
ing the question of whether PTFE can be used for
above-knee femoropopliteal bypass grafting as fol-
lows: it can be used safely in compromised patients
and those with a short life expectancy.8,15 However,
to answer the question of whether PTFE should be
the first choice in every patient, follow-up for this
prospective study must be completed to 5 years.
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